Thera-103

The term "Thera-103" is non-specific and appears to refer to multiple distinct investigational drugs or drug candidates, each with different developers, mechanisms of action, and therapeutic indications. Examples of drugs identified with similar numerical designations include TH103 (a VEGF inhibitor for wet age-related macular degeneration), TRX103 (an engineered Tr1 Treg cell therapy for Graft-versus-host disease and Crohn's Disease), TEQ103 (a small molecule for ERα+ breast cancer), TNX-103 (an oral formulation of levosimendan for pulmonary hypertension), TX103 (a CAR-T cell therapy for Grade 4 Glioma), CB-103 (an inhibitor of the CSL-NICD gene transcription factor complex for various cancers), and AVZO-103 (a bispecific antibody-drug conjugate for urothelial cancer). Due to this non-specificity, a single, unified description of mechanism, developer, or indication for "Thera-103" cannot be provided.